CSL Behring has struck a deal to buy uniQure’s late-phase hemophilia B gene therapy AMT-061 for $450 million upfront. The agreement will catapult CSL to the front of the race to bring a hemophilia B gene therapy to market, pitting it against companies including Pfizer. Source: Fierce Biotech 25/6/2020